IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Maurice Winn who wrote (1443)	1/23/1998 9:58:00 PM
From: Gregory Rasp	Read Replies (1) of 1762

Maurice. Sorry to bud in on your conversation. I am a radiation oncologist in the US and noticed the statement about neutrophil levels. Rituxan is not in our armory yet here. Can you elaborate? I would not think normal neutrophil levels would affect the drug. As for improving cure rates and relative dangers of untested therapies, we often run into this problem. When a disease has a small chance at cure (1-20% or so) there is little to lose in trying something about which only a little is known. On the other hand in diseases with high cure rates (70+% - I realize that anything less than 100% is low when you or a loved one is the patient), the risks are dramatically higher. We often radiate patients with Stage I or II intermediate and high grade NHL after they enter CR (complete response) to CHOP. We know that this improves cure rates 5-10% in some situations (bulky initial disease mainly). Nevertheless, we are still torn about doing so as we KNOW we will subject 100% of the patients to the toxicity of the treatment to help only 5-10%. It is a tough call to make. Yours Greg Rasp

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next